X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Xerava (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
XERAVA® (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 18, 2023
Details:
Xerava (eravacycline) is bacteriostatic which disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired MDR and are prevalent in China.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2022
Details:
Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TTY BIOPHARM CO LTD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 11, 2022
Details:
Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and are prevalent in China.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: TP-434
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Everest Medicines ompleted patient enrollment for its Phase 3 clinical trial of eravacycline (marketed as Xerava™ in the US and EU) for the treatment of complicated intra-abdominal infections (cIAI) in patients in China.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: La Jolla Pharmaceutical
Deal Size: $59.0 million Upfront Cash: $43.0 million
Deal Type: Acquisition June 24, 2020
Details:
Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: $55.0 million Upfront Cash: $55.0 million
Deal Type: Merger June 09, 2020
Details:
SOM Biotech has applied its AI based screening technology to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SOM Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 21, 2020
Details:
Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.
Lead Product(s): Eravacycline
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals
Deal Size: $26.9 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 16, 2020
Details:
The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Capital
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
